Danish Food Stock News

Pandora (CPSE:PNDORA) shares have experienced mixed trading over the past month, falling roughly 12% even as the company posted steady annual revenue and net income growth. Recent trends suggest investors are weighing current valuation against long-term performance history. See our latest analysis for Pandora. Shares of Pandora remain in the spotlight after a sharp 30-day share price return of -11.9%, which has brought the year-to-date decline to over 42%. Despite these slides, Pandora’s...

The cBrain A/S ( CPH:CBRAIN ) share price has fared very poorly over the last month, falling by a substantial 28%. The...

H. Lundbeck A/S ( CPH:HLUN B ) just reported healthy earnings but the stock price didn't move much. Our analysis...

Wondering if Novo Nordisk could be a bargain, overpriced, or hiding in plain sight? You are not alone in trying to answer that question. Let's cut through the noise together. After a wild ride including a 58.4% return over five years, the stock has dropped 11.3% in the last month and is now down 52.3% since the start of the year. This can shift how investors weigh both growth potential and risk. Recent headlines have been swirling around Novo Nordisk, with news of expanding production...

Gabriel Holding A/S ( CPH:GABR ) shareholders should be happy to see the share price up 29% in the last quarter. But...

Some FLSmidth & Co. A/S ( CPH:FLS ) shareholders may be a little concerned to see that the Group Chief Executive...

Earlier in November 2025, Scandinavian Tobacco Group A/S reported third quarter and nine-month results, revealing declines in both sales and net income compared to the prior year, and announced a narrowing of its full-year earnings guidance due to factors such as US consumer sentiment and currency fluctuations. The company highlighted that US retailer inventory decisions and changes in the USD/DKK exchange rate continue to create meaningful uncertainty for its full-year outlook. We'll...

In November 2025, Novo Nordisk began offering US cash payers early access to Wegovy at $349 per month and introduced substantial price reductions for select Ozempic doses, with introductory pricing as low as $199 monthly for certain strengths until the end of March 2026. This move reflects Novo Nordisk’s efforts to broaden patient access to its GLP-1 medicines and strengthen competitive positioning in the fast-evolving weight-loss drug market. We'll explore how this accelerated pricing...

GN Store Nord reported its third-quarter and nine-month 2025 results earlier this month, showing declines in sales to DKK3.96 billion and net income to DKK73 million for the quarter, with basic earnings per share dropping to DKK0.5. The company also set a cautious earnings outlook for 2025, projecting organic revenue growth between a 2% decline and a 2% increase, marking a period of subdued growth expectations amid ongoing challenges. We will examine how the recent dip in quarterly earnings...

NKT announced the successful completion of a turnkey repair for a 220 kV high-voltage subsea cable at the Beatrice Offshore Windfarm in Scotland, restoring export capacity just 38 days after contract signing, and also reported third-quarter earnings with sales of €936 million and net income of €67 million, both up year-over-year. This swift and technically complex cable repair, achieved well ahead of typical industry timelines and on a non-NKT cable, highlights the company’s expanding...

Rockwool (CPSE:ROCK B) updated its outlook for 2025, narrowing its expected EBIT margin to a range between 14% and 15%. This update follows previous guidance of below 16%, and revenue is still projected at last year's level. See our latest analysis for Rockwool. Rockwool’s updated margin outlook came right as the stock is navigating a tough stretch. The 1-month share price return is -13.1% and year-to-date the stock is down nearly 20%. Despite the recent slide, its 3-year total shareholder...

A.P. Møller Mærsk (CPSE:MAERSK B) shares have edged slightly higher today, continuing a fairly steady performance in recent sessions. Investors are watching the logistics giant’s moves closely, especially given recent shifts in the wider shipping industry. See our latest analysis for A.P. Møller - Mærsk. After a muted start to the year, A.P. Møller - Mærsk has held its ground amidst industry shifts, with its latest share price at DKK 12,550. While short-term share price returns have been...

Royal Unibrew reported its third quarter 2025 earnings, showing sales of DKK4.30 billion and net income of DKK558 million, with full-year guidance maintained and EBIT growth now expected at the high end of its target range. The company managed to expand revenues despite lower net income, emphasizing operational focus on efficiency and margin expansion going into the rest of the year. We'll explore how maintaining high-end EBIT growth guidance could influence Royal Unibrew's future prospects...

Vestas Wind Systems (CPSE:VWS) revealed it has secured new orders totaling 347 MW across the USA and Canada for undisclosed projects. This highlights consistent demand for the company’s wind energy solutions in key North American markets. See our latest analysis for Vestas Wind Systems. Momentum in Vestas Wind Systems’ share price has been undeniable lately, with a standout 22.9% 1-month share price return and a robust 45.4% year-to-date gain following news of new North American orders...

Embla Medical hf (CPSE:EMBLA) has launched a new prosthetic clinic in Kyiv, marking the beginning of a three-year partnership with the Government of Iceland. This initiative aims to improve prosthetic care for Ukrainian amputees impacted by the ongoing conflict. See our latest analysis for Embla Medical hf. Embla Medical hf’s new Kyiv clinic and partnership in Ukraine give investors plenty to consider, but market sentiment has yet to shift meaningfully. The stock’s recent 4.4% share price...

TORM plc recently increased its 2025 earnings guidance and approved a US$0.62 per share interim dividend for the third quarter, with a total expected payout of US$60.7 million. The updated guidance and dividend reflect management’s continued focus on capital returns, even as year-over-year earnings and revenues have declined. We’ll explore how TORM’s raised earnings outlook and dividend policy shape its investment narrative at a time of shifting profitability. AI is about to change...

As European markets navigate a landscape marked by cautious optimism following the reopening of the U.S. federal government, key indices like the STOXX Europe 600 have shown resilience with a modest rise, despite cooling sentiment around artificial intelligence investments. In this environment, discerning investors may find opportunities in lesser-known stocks that demonstrate strong fundamentals and adaptability to shifting economic conditions.

ALK-Abelló (CPSE:ALK B) just delivered its third quarter results, reporting higher sales and net income year-over-year. The company also announced an upgraded full-year outlook, which points to continued strength in its allergy and anaphylaxis business. See our latest analysis for ALK-Abelló. Reflecting this positive momentum, ALK-Abelló’s share price has surged 43% so far this year, while the past twelve months delivered an impressive 49% total shareholder return. The combination of solid...

Coloplast A/S ( CPH:COLO B ) will increase its dividend from last year's comparable payment on the 9th of December to...

Bavarian Nordic (CPSE:BAVA) drew investor focus after releasing its third quarter and nine-month 2025 results. The report showed a sharp rise in both sales and net income compared to last year. The company also updated its full-year outlook. See our latest analysis for Bavarian Nordic. Following upbeat earnings and a strengthened outlook, Bavarian Nordic’s share price has faced stiff headwinds. The 30-day return is -23.54%, and the year-to-date decline is 8.12%. Over the past year, the total...

Zealand Pharma (CPSE:ZEAL) just released its third quarter and nine-month results for 2025, showing a dramatic turnaround in both sales and profitability compared to the same periods last year. Investor attention is clearly focused on this shift. See our latest analysis for Zealand Pharma. After a tough start to the year, Zealand Pharma’s third quarter results have injected new optimism into the stock, with momentum clearly picking up as shown by the 24% share price return over the last 90...

Danske Bank has commenced a substantial share buy-back programme of up to DKK 5 billion, executing purchases of 211,000 shares on Nasdaq Copenhagen in the past week, which represents 1.849% of its share capital to date. Share buy-back programmes of this scale can often reflect management’s confidence in the company’s fundamentals and contribute to improving earnings per share through reduced share count. We’ll explore how Danske Bank’s active share repurchases could influence its investment...

On November 18, 2025, Genmab announced that the U.S. Food and Drug Administration granted full approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma, expanding its label and confirming prior accelerated approval based on Phase 3 study data. This milestone represents a significant advance for patients with this type of cancer, further strengthening Genmab’s position in developing innovative...

Novo Nordisk (CPSE:NOVO B) shares have been sliding over the past month, with the stock giving up 11%. For investors keeping an eye on long-term trends, this movement offers an opportunity to revisit the company’s valuation. See our latest analysis for Novo Nordisk. Novo Nordisk’s share price has faced significant pressure lately, extending a rough patch that’s seen an 11.03% drop over the last month and a steep 52.28% share price decline since the start of the year. In spite of this, the...